Anemia of prematurity: progress and prospects.
Anemia of prematurity: progress and prospects.
复制标题
早产儿贫血：进展与前景。
DOI：
--
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
K. Shannon
中科院分区：
文献类型：
--
作者：
K. Shannon
重组人促红细胞生成素（r-HuEPO）是儿科血液学家和儿科医生感兴趣的，因为它可能被证明是一种有效的替代输血在预防和治疗早产儿贫血。早产儿贫血是最有希望的初步临床试验。然而，可以想象，重组促红细胞生成素将在出生时给予低出生体重婴儿，以刺激内源性红细胞生成，从而防止一些红细胞输注所需的替代血液样本进行实验室检查。除了作为红细胞输注的治疗替代品的吸引力之外，重组人促红细胞生成素很可能成为第一个在新生儿医学中广泛使用的全新药物类别的成员。这些药物是通过克隆正常的人类基因并在实验室中表达而产生的。由于早产的许多问题是由发育不成熟引起的，因此用重组DNA技术产生的精确拷贝暂时替代关键蛋白质是一种可能对新生儿发病率和死亡率产生重大影响的方法。精心设计的，对照临床试验将是必不可少的，以确定新的代理人，如r-HuEPO在治疗早产儿的医疗问题的作用。
Recombinant human erythropoietin (r-HuEPO) is of interest to pediatric hematologists and neonatologists because it may prove to be an effective alternative to blood transfusions in preventing and treating anemia in premature infants. The anemia of prematurity is the most promising setting for initial clinical trials. However, it is conceivable that recombinant erythropoietin will be given at birth to low-birth-weight infants in an effort to stimulate endogenous erythropoiesis and thereby prevent some of the erythrocyte transfusions required to replace blood sampled for laboratory tests. Beyond its appeal as a therapeutic alternative to red blood cell transfusions, recombinant human erythropoietin is likely to be the first member of an entirely new class of drugs to be used widely in neonatal medicine. These are drugs produced by cloning normal human genes and expressing them in the laboratory. Because many of the problems of premature birth are caused by developmental immaturity, transiently replacing crucial proteins with exact copies produced by the techniques of recombinant DNA technology is an approach that may have a major impact on morbidity and mortality of neonates. Carefully designed, controlled clinical trials will be essential to determine the role of new agents like r-HuEPO in the treatment of medical problems of premature infants.